Correlation Between Larimar Therapeutics and Syndax Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Larimar Therapeutics and Syndax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Larimar Therapeutics and Syndax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Larimar Therapeutics and Syndax Pharmaceuticals, you can compare the effects of market volatilities on Larimar Therapeutics and Syndax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Larimar Therapeutics with a short position of Syndax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Larimar Therapeutics and Syndax Pharmaceuticals.

Diversification Opportunities for Larimar Therapeutics and Syndax Pharmaceuticals

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Larimar and Syndax is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Larimar Therapeutics and Syndax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Syndax Pharmaceuticals and Larimar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Larimar Therapeutics are associated (or correlated) with Syndax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Syndax Pharmaceuticals has no effect on the direction of Larimar Therapeutics i.e., Larimar Therapeutics and Syndax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Larimar Therapeutics and Syndax Pharmaceuticals

Given the investment horizon of 90 days Larimar Therapeutics is expected to under-perform the Syndax Pharmaceuticals. In addition to that, Larimar Therapeutics is 1.44 times more volatile than Syndax Pharmaceuticals. It trades about -0.15 of its total potential returns per unit of risk. Syndax Pharmaceuticals is currently generating about 0.04 per unit of volatility. If you would invest  1,252  in Syndax Pharmaceuticals on December 28, 2024 and sell it today you would earn a total of  66.00  from holding Syndax Pharmaceuticals or generate 5.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Larimar Therapeutics  vs.  Syndax Pharmaceuticals

 Performance 
       Timeline  
Larimar Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Syndax Pharmaceuticals 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain fundamental indicators, Syndax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Larimar Therapeutics and Syndax Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Larimar Therapeutics and Syndax Pharmaceuticals

The main advantage of trading using opposite Larimar Therapeutics and Syndax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Larimar Therapeutics position performs unexpectedly, Syndax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will offset losses from the drop in Syndax Pharmaceuticals' long position.
The idea behind Larimar Therapeutics and Syndax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk